B of A Securities Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $82
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Ashwani Verma has maintained a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and increased the price target from $74 to $82.
January 02, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies' stock rating remains a Buy according to B of A Securities, with an increased price target from $74 to $82, signaling confidence in the company's prospects.
The increase in price target by a reputable analyst typically indicates a positive outlook on the company's performance and is often taken as a bullish signal by the market. This can lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100